News

Analyst Predicts Apple's Growth Through Services and Innovation

Analyst Predicts Apple's Growth Through Services and Innovation

Analyst's Positive Outlook on Apple Inc

BofA Securities analyst Wamsi Mohan has a Buy rating on Apple Inc (NASDAQ: AAPL) with an ambitious price target of $256. This optimism is rooted in anticipated strong demand for new iPhone models, primarily due to advancements in technology like Generative AI, which seek to enhance user experience.

Iphone Upgrade Cycle and Revenue Growth

According to Mohan, the upcoming iPhone upgrade cycle set for fiscal years 2025 and 2026 is expected to significantly contribute to revenue growth. This is particularly important as consumers seek the latest hardware to better utilize new AI features. Additionally, the rise in revenue from Apple’s Services segment is anticipated to further support this trajectory.

Details of the Analyst's Price Target

The price target of $256 is predicated upon around 30 times Mohan's estimated earnings per share (EPS) of $8.47 for calendar year 2026. This multiple aligns with Apple's historical performance, which has ordinarily oscillated between 16 to 34 times. Mohan asserts that the higher price target is justified by a multi-year device upgrade cycle, Apple’s robust cash reserves, and the potential for diversification into new markets.

Impressive App Store Performance

In his analysis, Mohan highlighted key performance metrics for the App Store. Revenues in the first quarter surged to $2.9 billion, marking a 14.5% year-over-year increase. Additionally, downloads for iPhone and iPad grew by 7.6%, reaching a significant 3.1 billion during that timeframe.

Rapid Revenue Growth in October

October was particularly noteworthy, showcasing a global revenue increase of 15.1% in the App Store. In China alone, revenue grew by 6.7%. The average revenue generated per download also showed a healthy year-over-year growth of 6.4%, which underpins Mohan's Buy rating and optimistic predictions.

Diverse Revenue Streams in App Store Categories

Mohan further dissected the different categories within the App Store, revealing that entertainment revenue climbed 37% year-over-year. This segment emerged as the second-largest revenue category, eclipsed only by gaming, which contributed $1.4 billion—47% of total App Store revenue. The decline in gaming's share hints at a diversification trend as non-gaming applications become more lucrative.

Impact of the EU Digital Markets Act

The analyst also addressed the implications of the EU Digital Markets Act (DMA) on Apple’s App Store. Despite the 123% increase in Google Chrome downloads in the EU, which reached 15 million, the overall impact on Apple’s downloads remained minimal. Total App Store downloads in the EU still grew by 9%, with revenue soaring by 28% year-over-year, indicating resilient consumer behavior.

Promising Future for Apple's Services Segment

For the first fiscal quarter, Mohan is optimistic about a 13% year-over-year growth in Apple's total services revenue, projecting this growth will continue into the second quarter. This consistent performance from the Services segment signifies long-term viability and stability for Apple as more users engage with various service offerings.

Current Stock Performance

As of the latest market data, AAPL stock is trading down 0.64% at $221.49. While there might be fluctuations in share price, the comprehensive analysis provided by Mohan paints a picture of potential growth driven by innovative technology and service revenue.

Frequently Asked Questions

What is the current stock price of Apple Inc (AAPL)?

As per the latest information, AAPL stock is priced at $221.49, reflecting a slight decrease of 0.64%.

What is BofA analyst Wamsi Mohan's assessment of Apple?

Wamsi Mohan maintains a Buy rating on Apple Inc with a price target of $256 based on expected growth drivers like iPhone upgrades and services revenue.

How has Apple's App Store performed recently?

Apple's App Store saw a significant revenue increase, reaching $2.9 billion in the first quarter, demonstrating a 14.5% rise year-over-year.

Which App Store category experienced the largest growth?

The Entertainment category grew by 37% year-over-year, becoming the second-largest category in terms of revenue generation.

What is the outlook for Apple's services revenue?

The outlook is positive with a projected 13% year-over-year growth, highlighting the resilience of Apple's Services segment going forward.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Class Action Greenlighted Against Concordia for Title IX Violations

Updated Category News Views 87

Paving the Way for Equality in Campus Sports Ah, courts and colleges—two institutions you'd hope would play by the rules. But here we are, knee-deep in a legal battle with Concordia University Irvine (CUI) caught in the crosshairs of Title IX compliance issues. No surprise there when a federal court finally gave the nod for a class action to plow ahead. Class Action...

Continue Reading
AppLovin Legal Woes: A Deep Dive into Investor Claims

Updated Category News Views 104

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Continue Reading
Microsoft's Cloud Misstep: Recovery Plans in Focus

Updated Category News Views 149

Microsoft's Stumble Puts CIOs on Alert Thursday's Microsoft 365 outage, a wrench in the works for every firm that ties its daily operations to these cloud services, has brought some harsh truths to the table. On November 12, outages hit users hard, preventing access to Exchange Online mailboxes and sending ripples through Teams, SharePoint, Copilot, and Defender. You...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 118

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 202

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 162

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 179

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
Maritime Safety Urged After New Orleans Vessel Incident

Updated Category News Views 109

The Mississippi River saw a bit of drama near the Port of New Orleans when a river cruise turned into an unexpected rescue operation. Listen up, because incidents like this bring maritime safety right to the forefront; we can't ignore the waters that shape our daily lives here in the Big Easy. Navigating the Waters Safely Some 150 souls found themselves in a pickle when...

Continue Reading
Windward Bio Surges 68% in Nasdaq Debut

Updated Category News Views 134

Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...

Continue Reading
Ecopetrol Sidesteps Hefty Fines After Investigation Closure

Updated Category News Views 145

Colombian Watchdog Gives Ecopetrol a Pass It's like dodging a bullet in a duel at high noon. The Superintendency of Industry and Commerce (SIC) has finally closed its investigation into Ecopetrol S.A. and its subsidiaries, CENIT and OCENSA, after a probe two years in the making. The stakes were sky-high, folks. We're talkin' about just shy of 530 billion Colombian pesos...

Continue Reading

Top 5 Most Recently Viewed Articles

Kimbell Royalty Partners Engages Investors at Key Conferences

Updated Category News Views 101

Kimbell Royalty Partners to Attend Notable Investor Conferences Kimbell Royalty Partners, LP (NYSE: KRP) is a prominent owner of oil and natural gas mineral and royalty interests. The company proudly manages over 129,000 gross wells across multiple states. In an effort to strengthen investor relations and share its strategic outlook, Kimbell has announced its...

Continue Reading
Karsan's Autonomous Bus Debuts at Efteling Park

Updated Category News Views 72

A Leap Towards Autonomous Mobility What we have here is Karsan breaking new ground again. They've rolled out their Autonomous e-ATAK at Efteling, the famous theme park in the Netherlands. And that's not just any park—it's a place teeming with tourists, a hotspot demanding efficient transport. Yet, these folks aren't just cranking out fancy gadgets for showing off....

Continue Reading
EyePoint Pharmaceuticals Expands Workforce with Stock Options

Updated Category News Views 301

EyePoint Pharmaceuticals Expands Workforce with Stock Options EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a dynamic biopharmaceutical company, is on a mission to enhance the lives of patients facing serious retinal diseases. Recently, the company made a notable announcement regarding the expansion of its team through the granting of non-statutory stock options to new...

Continue Reading
IonQ Shares: Insights Into Their Current Market Performance

Updated Category News Views 204

Overview of IonQ's Current Stock Performance IonQ Inc. IONQ shares have seen a notable decline recently, continuing a downward trend that’s persisted over the last couple of weeks. As the company gears up to announce its second-quarter earnings, investors are closely monitoring the developments, particularly the anticipated shift in stock momentum. Market Sentiment and...

Continue Reading
Exploring the Promising CD47 Inhibitor Drug Market Growth

Updated Category News Views 40

Understanding the CD47 Inhibitor Drug Market Gaining insights into the CD47 inhibitor drug market is crucial for recognizing the changes and advancements in cancer immunotherapy. These drugs play a vital role in the battle against cancer by harnessing the body's immune system to identify and eliminate malignant cells. CD47's Role in Cancer CD47, often referred to as the...

Continue Reading